AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8792689 — intervention group
Group type: COMPARATOR
Intervention: Angiocath needle
Number of subjects: 40
Study 1619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (12 IU/d subcutaneously)
Number of subjects: 14
Study 1619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 14
Study 6435664 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 600 mg
Number of subjects: 12
Study 6435664 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg
Number of subjects: 12
Study 31474328 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 31474328 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 30382016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) for 14 days
Number of subjects: 758
Study 30382016 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 758
Study 30382016 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rifampicin
Number of subjects: 758
Study 30382016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study 28078869 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy laser therapy (HELT) at 650 nm
Number of subjects: 66
Study 28078869 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy laser therapy (HELT) at 810 nm
Number of subjects: 66
Study 28078869 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy laser therapy (HELT) at TRIAX (simultaneous emission of 810 nm, 980 nm, and 1064 nm)
Number of subjects: 66
Study 24131862 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage with endoscopic sphincterotomy (EST)
Number of subjects: 72
Study 24131862 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic nasobiliary drainage without endoscopic sphincterotomy (non-EST)
Number of subjects: 72
Study 22234018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) administered at a dosage of 10 mg/kg before CPB, on CPB, and after CPB
Number of subjects: 80
Study 22234018 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the same time intervals as TA
Number of subjects: 80
Study 20452234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cold retrograde blood cardioplegia (group B)
Number of subjects: 345
Study 20452234 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold retrograde crystalloid cardioplegia (group C)
Number of subjects: 345
Study 17707447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus artesunate (SP+AS)
Number of subjects: 190
Study 17707447 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 190
Study 15236424 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 15236424 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0
Study 11437176 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg/d)
Number of subjects: 63
Study 11437176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9516291 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 9516291 — intervention group
Group type: COMPARATOR
Intervention: Group Skills Training (GST)
Number of subjects: 0
Study 8041981 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine through a PCA pump (initial boluses of 50 mg + infusion of 10 mg/h with additional doses of 25 mg upon patient demand)
Number of subjects: 30
Study 8041981 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline serum through an epidural PCA system
Number of subjects: 30
Study 2532099 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoke tea
Number of subjects: 12
Study 2532099 — intervention group
Group type: COMPARATOR
Intervention: Ordinary tea
Number of subjects: 12
Study 1211921 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-20,961
Number of subjects: 20
Study 1211921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31852485 — intervention group
Group type: EXPERIMENTAL
Intervention: Elos‐Intrauma® nail (Group A)
Number of subjects: 323
Study 31852485 — intervention group
Group type: COMPARATOR
Intervention: Gamma 3‐Stryker® nail (Group B)
Number of subjects: 323
Study 28304313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy offered once weekly for 16 weeks
Number of subjects: 63
Study 28304313 — intervention group
Group type: COMPARATOR
Intervention: Group recreational therapy
Number of subjects: 63
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste (TAP) at 1000 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Antibiotic Paste (DAP) at 1000 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste (TAP) at 1 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Antibiotic Paste (DAP) at 1 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste (TAP) at 0.5 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Antibiotic Paste (DAP) at 0.5 mg/mL
Number of subjects: 45
Study 25887806 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of DAP
Number of subjects: 45
Study 25887806 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study 24195278 — intervention group
Group type: EXPERIMENTAL
Intervention: Peracetic acid (15 microl/l and 45 microl/l)
Number of subjects: 0
Study 24195278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramine T (2 mg/l)
Number of subjects: 0
Study 24195278 — intervention group
Group type: EXPERIMENTAL
Intervention: Peracetic acid (45 microl/l)
Number of subjects: 0
Study 24195278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22133996 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN/FU + CDDP
Number of subjects: 114
Study 22133996 — intervention group
Group type: COMPARATOR
Intervention: IFN/FU
Number of subjects: 114
Study 19226304 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 4
Study 15894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based polychemotherapy (e.g., FAC or FEC) for about 6 months
Number of subjects: 8000
Study 15894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for about 5 years
Number of subjects: 8000
Study 15894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation or suppression
Number of subjects: 8000
Study 15894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years) following anthracycline-based chemotherapy
Number of subjects: 8000
Study 15894097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy followed by tamoxifen
Number of subjects: 8000
Study 12165887 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 24
Study 12165887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9539602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus verapamil
Number of subjects: 100
Study 9539602 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 100
Study 9539602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus verapamil (reverse order)
Number of subjects: 100
Study 9539602 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (reverse order)
Number of subjects: 100
Study 7840379 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm partial shunts
Number of subjects: 18
Study 7840379 — intervention group
Group type: COMPARATOR
Intervention: 16-mm total shunts
Number of subjects: 18
Study 7840379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient hepatic blood flow
Number of subjects: 18
Study 7840379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient hepatic blood flow > 325 mL/min
Number of subjects: 18
Study 2195532 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyfrequent oscillation method (reactance, resistance between 2 and 52 Hz)
Number of subjects: 30
Study 2195532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyplethysmography (Raw, FEV1)
Number of subjects: 30
Study 2195532 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen pressure (tc‐PO2)
Number of subjects: 30
Study 2195532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of bodyplethysmography and polyfrequent oscillation method
Number of subjects: 30
Study 623129 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin, methicillin and gentamicin
Number of subjects: 126
Study 623129 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin and cephalothin
Number of subjects: 126
Study 623129 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antibiotics due to specific indications or counterindications
Number of subjects: 126
Study 623129 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial responders
Number of subjects: 126
Study 623129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 126
Study 30542782 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfluidic technique (Fertile Chip®)
Number of subjects: 122
Study 30542782 — intervention group
Group type: COMPARATOR
Intervention: Conventional swim-up techniques
Number of subjects: 122
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol fumarate (FP/FORM; Flutiform®) pressurized metered-dose inhaler (pMDI)
Number of subjects: 307
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM K‐haler® (breath-triggered inhaler)
Number of subjects: 307
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM pMDI
Number of subjects: 307
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FORM K‐haler®
Number of subjects: 307
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 307
Study 28683212 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐haler BTI
Number of subjects: 307
Study 25631485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 497
Study 25631485 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution (HA)
Number of subjects: 497
Study 23883675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum high-fiber, low-fat diet and daily exercise (2-2.5 h)
Number of subjects: 33
Study 21333607 — intervention group
Group type: EXPERIMENTAL
Intervention: PEARLS intervention (home-based collaborative care consisting of problem-solving treatment, behavioral activation, and psychiatric consultation)
Number of subjects: 80
Study 21333607 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 19320645 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Training programme
Number of subjects: 27
Study 19320645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 17069905 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stents (PES)
Number of subjects: 25
Study 17069905 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 25
Study 15089811 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (1 mg oral dose) under fasting conditions
Number of subjects: 14
Study 15089811 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (1 mg oral dose) after a high fat meal
Number of subjects: 14
Study 15089811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11575286 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide and pamidronate (60 mg intravenously every 12 weeks)
Number of subjects: 47
Study 11575286 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 47
Study 9490236 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg)
Number of subjects: 189
Study 9490236 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol plus multivitamins
Number of subjects: 189
Study 9490236 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (beta‐carotene 30000 IU, vitamin C 500 mg, and vitamin E 700 IU)
Number of subjects: 189
Study 9490236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 7945735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of oral yohimbine
Number of subjects: 7
Study 7945735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3061885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bd
Number of subjects: 42
Study 3061885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3061885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at night
Number of subjects: 42
Study 28856476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate treatment
Number of subjects: 72
Study 28856476 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 27501966 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 6 mg
Number of subjects: 0
Study 27501966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25701774 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDRP + MVP
Number of subjects: 768
Study 25701774 — intervention group
Group type: COMPARATOR
Intervention: DDDR
Number of subjects: 768
Study 22930253 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session structured multidisciplinary intervention
Number of subjects: 131
Study 22930253 — intervention group
Group type: COMPARATOR
Intervention: Standard care arm
Number of subjects: 131
Study 22930253 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session structured multidisciplinary intervention followed by 10 brief telephone counseling sessions
Number of subjects: 131
Study 20716738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge (2 sponges, total gentamicin of 260 mg)
Number of subjects: 1502
Study 20716738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1502
Study 18085275 — intervention group
Group type: EXPERIMENTAL
Intervention: LDIH (60-minute daily exposures to normobaric 12% O2)
Number of subjects: 10
Study 18085275 — intervention group
Group type: EXPERIMENTAL
Intervention: SDIH (twelve 5-minute bouts of normobaric 12% O2 separated by 5-minute bouts of room air)
Number of subjects: 10
Study 15734867 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 12
Study 15734867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11870809 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of macrophage colony-stimulating factor (M-CSF) during intensive chemotherapies
Number of subjects: 0
Study 11870809 — intervention group
Group type: COMPARATOR
Intervention: Placebo during intensive chemotherapies
Number of subjects: 0
Study 10367219 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (asa) 160 mg/die plus low-intensity oral anticoagulation (target INR: 1.5-2.5)
Number of subjects: 101
Study 10367219 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (pico) 300 mg/tid plus low-intensity oral anticoagulation
Number of subjects: 101
Study 10367219 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of major clinical events plus major hemorrhagic episodes
Number of subjects: 101
Study 7563451 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA (alteplase) 1.1 mg/kg
Number of subjects: 620
Study 7563451 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA (alteplase)
Number of subjects: 620
Study 7563451 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 620
Study 2188797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular flupenthixol decanoate (5 to 10 mg/fortnight)
Number of subjects: 57
Study 2188797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amitriptyline (75 to 150 mg/day)
Number of subjects: 57
Study 2188797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 57
Study 7002374 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram beclomethasone dipropionate a day for 2 weeks
Number of subjects: 183
Study 7002374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 31125404 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted alfalfa hay (RAH)
Number of subjects: 54
Study 31125404 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted beet pulp (RBP)
Number of subjects: 54
Study 31125404 — intervention group
Group type: COMPARATOR
Intervention: Corn silage (CS)
Number of subjects: 54
Study 26046808 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with initial restrictive pressures (IRP) of 40 or 60 mmHg
Number of subjects: 34
Study 26046808 — intervention group
Group type: COMPARATOR
Intervention: Control session (no blood flow restriction)
Number of subjects: 34
Study 25793351 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 98
Study 25793351 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 98
Study 24261310 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive laser therapy (red or infrared) for 5 days starting on the 1st day of infusion
Number of subjects: 40
Study 24261310 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic laser therapy (red or infrared) only if mucositis developed
Number of subjects: 40
Study 21074333 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scans (initial and follow-up)
Number of subjects: 51
Study 19476649 — intervention group
Group type: EXPERIMENTAL
Intervention: NFG (n = 19)
Number of subjects: 73
Study 19476649 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG (n = 19)
Number of subjects: 73
Study 19476649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (n = 35)
Number of subjects: 73
Study 17298645 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota day clinic treatment
Number of subjects: 148
Study 17298645 — intervention group
Group type: COMPARATOR
Intervention: Public out‐patient alcohol clinic treatment
Number of subjects: 148
Study 15129791 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based testing
Number of subjects: 74
Study 15129791 — intervention group
Group type: COMPARATOR
Intervention: External cardiac defibrillation
Number of subjects: 74
Study 11295901 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation with exercise
Number of subjects: 191
Study 11295901 — intervention group
Group type: EXPERIMENTAL
Intervention: MedX rehabilitative neck exercise
Number of subjects: 191
Study 11295901 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation alone
Number of subjects: 191
Study 10633536 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture (U) for 20 min
Number of subjects: 24
Study 10633536 — intervention group
Group type: COMPARATOR
Intervention: Sitting posture (S) for 20 min
Number of subjects: 24
Study 10633536 — intervention group
Group type: COMPARATOR
Intervention: Lying posture (L) for 20 min
Number of subjects: 24
Study 10633536 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture (U)
Number of subjects: 24
Study 10633536 — intervention group
Group type: COMPARATOR
Intervention: Sitting posture (S) and Lying posture (L)
Number of subjects: 24
Study 8958495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 41
Study 8958495 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 41
Study 7555292 — intervention group
Group type: EXPERIMENTAL
Intervention: Total McKee-Farrar hip replacement
Number of subjects: 0
Study 7555292 — intervention group
Group type: COMPARATOR
Intervention: Nonoperated arthritic hips and normal hips (control group)
Number of subjects: 0
Study 3893128 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mEq/l sodium dialysate
Number of subjects: 7
Study 3893128 — intervention group
Group type: EXPERIMENTAL
Intervention: 143 mEq/l sodium dialysate
Number of subjects: 7
Study 3893128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium gradient dialysate
Number of subjects: 7
Study 3893128 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 7
Study 28074421 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed combination antiretroviral therapy (DOT-cART)
Number of subjects: 356
Study 28074421 — intervention group
Group type: COMPARATOR
Intervention: No DOT
Number of subjects: 356
Study 26324250 — intervention group
Group type: COMPARATOR
Intervention: Nicotine concentration of 0 mg/mL
Number of subjects: 16
Study 26324250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 8 mg/mL
Number of subjects: 16
Study 26324250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 18 mg/mL
Number of subjects: 16
Study 26324250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 36 mg/mL
Number of subjects: 16
Study 25195084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5th generation troponin T reporting
Number of subjects: 2000
Study 25195084 — intervention group
Group type: COMPARATOR
Intervention: 4th generation troponin T reporting
Number of subjects: 2000
Study 22464410 — intervention group
Group type: EXPERIMENTAL
Intervention: OC+SPL (2 mg chlormadinone acetate/30 mcg ethinylestradiol combined with spironolactone)
Number of subjects: 50
Study 22464410 — intervention group
Group type: COMPARATOR
Intervention: OC (2 mg chlormadinone acetate/30 mcg ethinylestradiol)
Number of subjects: 50
Study 22464410 — intervention group
Group type: EXPERIMENTAL
Intervention: OC
Number of subjects: 50
Study 22464410 — intervention group
Group type: COMPARATOR
Intervention: OC+SPL
Number of subjects: 50
Study 20506712 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Probiotic (LP)
Number of subjects: 150
Study 20506712 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed Probiotic (KP)
Number of subjects: 150